Papers
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
BMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.7020.1602 (Published 16 December 1995) Cite this as: BMJ 1995;311:1602Related articles
- No related articles found.
See more
- Dengue: Argentinians turn to homemade repellent amid surge in casesBMJ April 17, 2024, 385 q885; DOI: https://doi.org/10.1136/bmj.q885
- Devolved powers for Greater Manchester led to some health improvements, study showsBMJ March 28, 2024, 384 q767; DOI: https://doi.org/10.1136/bmj.q767
- Long waits in child mental health are a “ticking time bomb” regulator warnsBMJ March 22, 2024, 384 q724; DOI: https://doi.org/10.1136/bmj.q724
- Doctors report big rise in patients with illness because of socioeconomic factorsBMJ March 01, 2024, 384 q538; DOI: https://doi.org/10.1136/bmj.q538
- Diphtheria: WHO publishes first ever guidance following outbreaksBMJ February 14, 2024, 384 q407; DOI: https://doi.org/10.1136/bmj.q407
Cited by...
- Enhancing Mask Activity in Dopaminergic Neurons Extends Lifespan in Flies
- Prescribing in Parkinson's disease: a story of hope and adverse events
- The scientific and clinical basis for the treatment of Parkinson disease (2009)
- Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
- Agonist or levodopa for Parkinson disease?: Ultimately, it doesn't matter; neither is good enough
- Estimated life expectancy of Parkinson's patients compared with the UK population
- Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort
- Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease
- Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
- Using monoamine oxidase type B inhibitors in Parkinson's disease
- Measuring motor complications in clinical trials for early Parkinson's disease
- Evaluating drug treatments for Parkinson's disease: how good are the trials?
- Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial
- Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology
- Parkinsonism in Ontario: Increased mortality compared with controls in a large cohort study
- Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial
- An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
- Selegiline and mortality in subjects with Parkinson's disease: A longitudinal community study
- Selegiline and Parkinson's disease: It's deja vu--again
- Pharmacological treatment of Parkinson's disease
- Recent advances: Neurology
- Developments in the treatment of Parkinson's disease
- Respiratory aspects of neurological disease
- Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease
- Mortality in people taking selegiline: observational study
- Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry
- Moclobemide and selegeline in the treatment of depression in Parkinson's disease
- Unexpected findings of study of selegiline have not been treated with caution its authors advised
- Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease
- Causes of death need confirmation
- Patients taking selegiline may have received more levodopa than necessary
- Parkinson's disease is rarely a primary cause of death
- Selegiline may be toxic in presence of increased dopamine concentrations
- Stopping selegiline may lead to problems for patients
- Authors' reply
- Patients taking selegiline may have received more levodopa than necessary
- Selegiline may be toxic in presence of increased dopamine concentrations
- Selegiline May Not Be So Good for Early Parkinsonism
- SELEGILINE MAY NOT BE SO GOOD FOR EARLY PARKINSONISM